Chemistry:Deuterated testosterone
| Clinical data | |
|---|---|
| Other names | AVA-291; AVA291; d-Testosterone; d3-Testosterone; d3-T; Deutestosterone; Testosterone-19-d3; 17β-Hydroxyandrost-4-en-3-one-19,19,19-D3 |
| Routes of administration | Oral, transdermal, parenteral[1] |
| Drug class | Androgen; Anabolic steroid |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H28O2 |
| Molar mass | 288.431 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deuterated testosterone (developmental code name AVA-291), also known as d3-testosterone (d3-T), is an androgen or androgen receptor agonist which is under development for the treatment of breast cancer, female sexual dysfunction, hypogonadism, decreased libido, fatigue, and muscular atrophy.[1][2][3][4][5][6][7][8] It is taken orally, transdermally, or parenterally.[1]
The drug is an isotopologue of testosterone.[1][2][8] More specifically, the three hydrogen atoms on the C19 methyl group have been replaced with the deuterium isotopes.[1][8] Unlike testosterone, deuterated testosterone is highly resistant to metabolism into estradiol by aromatase, showing a half-life that is 4 to 7 times longer than that of testosterone in an aromatase-containing system in vitro (55.9–79.9 minutes vs. 7.7–18.5 minutes, respectively).[7][8] On the other hand, they were metabolized at similar rates in rat and human hepatocytes.[7][8][4] In addition, deuterated testosterone had similar potency and efficacy as testosterone as an androgen receptor agonist in vitro.[7][8] As such, deuterated testosterone is expected to retain activity as an androgen similarly to testosterone but to lack or have greatly reduced estrogenic activity.[4][7][8] Accordingly, deuterated testosterone showed 1,000-fold lower potential in stimulating breast cancer cell proliferation compared to testosterone.[4][9]
The chemical synthesis of deuterated testosterone has been described.[10][11][8]
Deuterated testosterone was first described in the scientific literature by 1978.[11] It is under development by Lennham Pharmaceuticals and Aviva Biopharm.[1][2][3][12] As of December 2025, the drug is in the preclinical research stage of development.[1][2][3] A phase 1 trial is being planned for early 2026.[2][4] Deuterated testosterone was patented in 2021.[6][8] It is expected to have improved tolerability and safety relative to testosterone in certain contexts, for instance avoiding gynecomastia (male breast development) or treating estrogen-sensitive breast cancer.[4][9][7][8]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Deuterated testosterone". 28 December 2025. https://adisinsight.springer.com/drugs/800065467.
- ↑ 2.0 2.1 2.2 2.3 2.4 "AVA 291". 1 August 2025. https://adisinsight.springer.com/drugs/800083242.
- ↑ 3.0 3.1 3.2 "Delving into the Latest Updates on d-Testosterone with Synapse". 16 May 2025. https://synapse.patsnap.com/drug/374be0a898364758b6005a1cf515d315.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "FDA provides guidance on development pathway for testosterone therapy for women". 27 January 2026. https://www.urologytimes.com/view/fda-provides-guidance-on-development-pathway-for-testosterone-therapy-for-women.
- ↑ "Weighty times ahead for the lab?". TIAFT Bulletin 52 (4). 2022. https://www.bioscientia.de/media/qr0onwah/deuterated-drugs-weighty-times_tiaft-bulletin_2022.pdf. Retrieved 27 January 2026.
- ↑ 6.0 6.1 "Lennham discloses deuterated testosterone compound". 11 November 2021. https://www.bioworld.com/articles/686257-lennham-discloses-deuterated-testosterone-compound?v=preview.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "MON-261 Characterization of d3-Testosterone, A Novel, Non-Aromatizing Androgen". Journal of the Endocrine Society 9 (Supplement_1). 22 October 2025. doi:10.1210/jendso/bvaf149.1839. ISSN 2472-1972.
- ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 "Deuterated forms of testosterone and methods of use". 23 March 2021. https://patents.google.com/patent/US11202785B1.
- ↑ 9.0 9.1 "Aviva to advance, announce new data for AVA-291 women's testosterone therapy". 27 January 2026. https://www.contemporaryobgyn.net/view/aviva-to-advance-announce-new-data-for-ava-291-women-s-testosterone-therapy.
- ↑ "A unified total synthesis route to 18-trideuterated and/or 19-trideuterated testosterone, androstenedione and progesterone". Steroids 205. May 2024. doi:10.1016/j.steroids.2024.109391. PMID 38437943.
- ↑ 11.0 11.1 "Synthesis of trideuterated testosterone labeled selectively at the C-19 angular methyl group". Journal of Labelled Compounds and Radiopharmaceuticals 14 (5): 783–791. 1978. doi:10.1002/jlcr.2580140517. ISSN 0362-4803. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jlcr.2580140517. Retrieved 27 January 2026.
- ↑ "Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025". 14 July 2025. https://www.businesswire.com/news/home/20250714405897/en/Aviva-Biopharm-Inc.-Unveils-Groundbreaking-Pre-Clinical-Data-on-d3-T-a-First-in-Class-Testosterone-Therapy-for-Women-at-ENDO-2025.
External links
- d-Testosterone - Pipeline - Lennham Pharmaceuticals
- The Science / Our Innovation (Meet d3-Testosterone: A Molecular Reinvention) - Aviva Bio
- Lennham Pharmaceuticals Announces Discovery of Next Generation Testosterone Candidate - Lennham Pharmaceuticals
{{Navbox
| name = Androgens and antiandrogens | title = Androgens and antiandrogens | state = collapsed | listclass = hlist | groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)
| list1 =
| group2 = Antiandrogens | list2 = {{Navbox|child | groupstyle = text-align:center; | groupwidth = 9em;
| group1 = AR antagonists | list1 =
- Steroidal: Abiraterone acetate
- Canrenone
- Chlormadinone acetate
- Cyproterone acetate
- Delmadinone acetate
- Dienogest
- Drospirenone
- Medrogestone
- Megestrol acetate
- Nomegestrol acetate
- Osaterone acetate
- Oxendolone
- Potassium canrenoate
- Spironolactone
- Nonsteroidal: Apalutamide
- Bicalutamide
- Cimetidine
- Darolutamide
- Enzalutamide
- Flutamide
- Ketoconazole
- Nilutamide
- Seviteronel†
- Topilutamide (fluridil)
| group2 = Steroidogenesis| list2 =
inhibitors
| 5α-Reductase | |
|---|---|
| Others |
| group3 = Antigonadotropins | list3 =
- D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
- Estrogens (e.g., bifluranol, [[diethylstilbestrol, estradiol, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)
- GnRH agonists (e.g., leuprorelin)
- GnRH antagonists (e.g., cetrorelix)
- Progestogens (incl., chlormadinone acetate, [[cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, [[Chemistry:Medroxyprogesterone medroxyprogesterone acetate, Chemistry:Megestrol acetate|megestrol acetate]])
| group4 = Others | list4 =
- Androstenedione immunogens: Androvax (androstenedione albumin)
- Ovandrotone albumin (Fecundin)
}}
| liststyle = background:#DDDDFF;| list3 =
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
}}
